PCN171 COST AND HEALTHCARE RESOURCE UTILIZATION (HRU) RESULTING FROM IMMUNE-RELATED ADVERSE EVENTS (IRAES) AMONG PATIENTS RECEIVING IMMUNE CHECKPOINT INHIBITORS (ICIS)
نویسندگان
چکیده
منابع مشابه
Corrigendum: Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
The indications of immune checkpoint inhibitors (ICIs) are set to rise further with the approval of newer agent like atezolimumab for use in patients with advanced stage urothelial carcinoma. More frequent use of ICIs has improved our understanding of their unique side effects, which are known as immune-related adverse events (irAEs). The spectrum of irAEs has expanded beyond more common manife...
متن کاملReview: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer.
متن کامل
A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors.
BACKGROUND There are limited data about the quality of immune-related adverse event (irAE) reporting in immune checkpoint inhibitor (ICI) clinical trial publications. METHODS A systematic search of citations from Medline, EMBASE and Cochrane databases identified prospective clinical trials involving ICIs in advanced solid tumors from 2003 to 2013. A 21-point quality score (QS) was adapted fro...
متن کاملRenal Toxicity Related to Immune Checkpoint Inhibitors
As early as the 18th century, physicians noticed that some cancer patients went into remission after developing fevers from infections. This led to the idea that the immune system, which protects from infection, might also fight cancer. What is now known as “immunotherapy” is a treatment that targets the immune system to recognize and eradicate cancer cells. Modern immunotherapy has focused on ...
متن کاملClinical assessment of immune-related adverse events
Immunotherapy through checkpoint inhibitors is now standard practice for a growing number of cancer types, supported by overall improvement of clinical outcomes and better tolerance. One anti-CTLA-4 antibody (ipilimumab), two anti-PD-1 antibodies (pembrolizumab and nivolumab) and three anti-PD-L1 antibodies (atezolizumab, avelumab and durvalumab) have been approved for clear benefits across div...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Value in Health
سال: 2019
ISSN: 1098-3015
DOI: 10.1016/j.jval.2019.09.367